An Open-Label, Multicenter, Multinational Study to Assess the Feasibility of Switching Therapy From Pramipexole or Ropinirole to the Rotigotine Transdermal System and Its Effect on Motor and Non-Motor Symptoms in Subjects With Advanced Idiopathic Parkinson's Disease Phase 4

Trial Profile

An Open-Label, Multicenter, Multinational Study to Assess the Feasibility of Switching Therapy From Pramipexole or Ropinirole to the Rotigotine Transdermal System and Its Effect on Motor and Non-Motor Symptoms in Subjects With Advanced Idiopathic Parkinson's Disease Phase 4

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Jun 2014

At a glance

  • Drugs Rotigotine (Primary) ; Levodopa/benserazide; Levodopa/carbidopa; Pramipexole; Ropinirole
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Sponsors UCB
  • Most Recent Events

    • 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 14 Nov 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top